Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Sangamo Biosciences ( (SGMO) ).
On September 4, 2025, Sangamo Therapeutics announced updated clinical data from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease, presented at ICIEM2025 in Kyoto. The study showed promising results, with patients demonstrating stable cardiac function and significant improvements in disease severity and quality of life. The company is preparing a Biologics License Application for accelerated approval, targeting submission in early 2026, contingent on securing additional funding. These developments could enhance Sangamo’s position in the gene therapy market and offer new treatment options for Fabry disease patients.
The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
Spark’s Take on SGMO Stock
According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.
Sangamo Biosciences’ stock score is primarily impacted by its poor financial performance, characterized by declining revenue and profitability, and a weak balance sheet. While there are positive developments in clinical trials and strategic initiatives, these are overshadowed by financial instability and the need for additional funding. Technical indicators provide some neutral signals, but valuation metrics suggest the stock is overvalued.
To see Spark’s full report on SGMO stock, click here.
More about Sangamo Biosciences
Sangamo Therapeutics, Inc. operates in the biotechnology industry, focusing on gene therapy solutions. The company develops therapies for genetic diseases, with a particular emphasis on conditions like Fabry disease.
Average Trading Volume: 5,827,621
Technical Sentiment Signal: Sell
Current Market Cap: $162.7M
Learn more about SGMO stock on TipRanks’ Stock Analysis page.